NF2 and cancer: Next, having established a quantifiable cancer-relevant phenotype robustly driven by NF2 loss, we tested spheroid growth in the presence of YAP/TAZ-TEAD inhibitors to quantify the impact of inhibition on the tumorigenic capacity of spheroids.